Patients will be screened to distinguish those with central precocious puberty and those with pseudosexual precocity due to adrenal or gonadal disease. Those patients found to have central precocious puberty will undergo a modified gonadotropin-releasing hormone (GnRH) test with acqueous leuprolide acetate, a GnRH antagonist, and serial bloods will be drawn for LH and FSH over the subsequent 24 hours. A long-acting form of leuprolide acetate will then be administered intramuscularly on a monthly basis for six months.
Showing the most recent 10 out of 470 publications